You are viewing the site in preview mode

Skip to main content

Advertisement

Table 5 Association of treatment factors and treatment toxicity

From: Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity

  Acute toxicity max grade (n = 37) Late toxicity max grade (n = 32)
0 1–2 3 p-value 0 2 4 p-value
Number of fiducials†
 0–1 1 6 0 0.0002* 4 1 2 0.01*
 2–4 10 17 3   22 1 2  
Treatment days †
 3 11 20 3 0.37 25 2 2 0.012*
 4–7 0 3 0   1 0 2  
Previous surgery†
 Yes 1 5 0 0.47 4 0 1 0.68
 No 10 18 3   22 2 3  
Previous irradiation†
 Yes 0 7 1 0.11 6 0 0 0.43
 No 11 16 2   20 2 4  
Min dose to PTV†
  < 22.35Gy 5 10 2 0.75 9 2 2 0.17
  ≥ 22.35Gy 6 11 1   17 0 2  
SABR purpose†
 Sole primary 1 6 0 0.064 6 1 0 0.62
 Adjuvant 6 4 1   7 0 1  
 Consolidation 4 6 1   8 1 1  
 Retreat 0 5 2   5 0 2  
 Treatment time (mins) 77.5 69.9 68.3 0.570 67.7 59.5 83.0 0.045*
 PTV (cc) ‡ 93.5 72.1 67.9 0.355 77.2 61.5 79.3 0.875
 PTV min dose (cGy) ‡ 2342.6 2227.6 2115.8 0.605 2317.7 1901.5 2332.4 0.396
 PTV max dose (cGy) ‡ 3951.3 3974.7 4149.2 0.8819 4120.6 3920.5 3861.9 0.622
 PTV mean dose (cGy) ‡ 3151.9 3118.0 3241.9 0.879 3225.4 3085.6 3015.0 0.493
Prescription dose (cGy) ‡ 2736.4 2647.8 2700.0 0.735 2740.4 2700.0 2612.5 0.7067
 Prescription isodose (%) ‡ 69.6 67.5 65.3 0.554 67.0 69.0 68.3 0.882
 Percentage cover (%) ‡ 96.1 97.0 97.3 0.771 97.1 88.1 91.1 0.002*
 BED (Gy10) ‡ 52.3 49.2 52.0 0.650 52.1 51.0 49.0 0.811
 HI ‡ 1.44 1.50 1.54 0.523 1.51 1.46 1.47 0.833
  1. *Statistically significant at 0.05% level † Numbers are frequencies, tested for association using Chi-squared test; ‡ Numbers are means, tested for association using ANOVA